Literature DB >> 35313492

The data on molecular docking of cinnamic acid amide on dengue viral target NS2B/NS3.

Nadia Mohamed Yusoff1, Asnuzilawati Asari1,2, Siti Nor Khadijah Addis1.   

Abstract

A natural occurring class compound, cinnamic acid is composed of a benzene ring, an alkene double bond and an acrylic acid functional group. Due to the feasibility of its structure modifications with a variety of compounds, cinnamic acids have been actively explored to improve their biological efficacy. Cinnamic acid derivatives have been reported to exhibit an antimicrobial property. Despite the beneficial properties of cinnamic acid derivatives, the antiviral activity of the amide derivatives especially against the dengue virus is poorly defined. Herein, the cinnamic amide derivatives were evaluated for their potential as an anti-dengue virus through the in-silico analysis of the derivatives. This data aimed to analyze the interactions of the derivatives against the non-structural protein of viral target, dengue virus type 2 (DENV-2) NS2B/N3. The evaluation was based on binding affinity, interaction type (bond type and distance) and interaction with amino acids. Three derivatives (CAA15, CAA16 and CAA17) with the best docking score were reported. Enhanced understanding of the interaction acquired from this analysis provide a useful information on for the prediction of the binding behavior affinity of cinnamic amide derivatives and is ultimately useful in the rational design of drugs to synthesis new compounds with the potential benefits against DENV-2.
© 2022 The Author(s). Published by Elsevier Inc.

Entities:  

Keywords:  Autodock; Cinnamic amide; Dengue; In-silico; NS2B/NS3

Year:  2022        PMID: 35313492      PMCID: PMC8933529          DOI: 10.1016/j.dib.2022.108036

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table

Value of the Data

The data provide on the interaction between cinnamic amide derivatives with the viral target NS2B/NS3 protease (NS2B/NS3pro) protein. The in-silico analysis of the antiviral properties of cinnamic amide derivatives may indicate the direction for future research in the field of anti-dengue therapy. The screening data help minimized research time considerably by enable the researchers to rapidly identify promising compounds and its interaction with the viral target. The data are useful for research scholars with insufficient software and hardware requirements which not affordable by them. The data can facilitate on the direction of the functional design of cinnamic amide derivatives specifically to target dengue virus infection.

Data Description

The predominant circulating dengue virus (DENV) serotype is dengue virus type 2 (DENV-2). Although many research have been conducted in finding an effective antiviral against it, there is still no specific treatment currently available [1]. Nonetheless, there is emerging interest in development of an effective inhibitor against the NS2b/NS3 serine protease which responsible for seven different polyprotein cleavages in the virus life cycle [2]. Cinnamic acid (Fig. 1) occur in all green plant and is known for their various biological activities [3,4]. The provided docking data of 30 cinnamic amide derivatives against DENV-2 may be useful to develop new drug candidates for the treatment of DENV infections. In this article, Table 1 provides the details of the viral target (as retrieved from Wichapong et al [5].), Table 2 provides the structure of cinnamic amide derivatives, while the free binding energy, interaction type and bond length of the docking are shown in Table 3. The 3D interaction of the top 3 best-docked compounds with the target are shown in Fig. 2, Fig. 3, Fig. 4. The selection was made based on the lowest free binding energy with the highest number of Hydrogen bonding.
Fig. 1

Structure of cinnamic acid.

Table 1

DENV target used in docking.

ProteinPDB IDResolution
1.NS2B-NS3 ProteaseModel – Homologous crystal structure of DENV-2 NS2B/NS3pro [4]
Table 2

List of cinnamic acids and cinnamic amide derivatives.

No.LigandStructure
1.CAA01Image, table 2
2.CAA02Image, table 2
3.CAA03Image, table 2
4.CAA04Image, table 2
5.CAA05Image, table 2
6.CAA06Image, table 2
7.CAA07Image, table 2
8.CAA08Image, table 2
9.CAA09Image, table 2
10.CAA10Image, table 2
11.CAA11Image, table 2
12.CAA12Image, table 2
13.CAA13Image, table 2
14.CAA14Image, table 2
15.CAA15Image, table 2
16.CAA16Image, table 2
17.CAA17Image, table 2
18.CAA18Image, table 2
19.CAA19Image, table 2
20.CAA20Image, table 2
21.CAA21Image, table 2
22.CAA22Image, table 2
23.CAA23Image, table 2
24.CAA24Image, table 2
25.CAA25Image, table 2
26.CAA26Image, table 2
27.CAA27Image, table 2
28.CAA28Image, table 2
29.CAA29Image, table 2
30.CAA30Image, table 2
Table 3

Cinnamic amide derivatives and their interactions.

Sr. No.LigandFree Binding energy, FEB (kcal/mol)InteractionType of interactionBond distance (Å)
1.CAA01−6.66ILE B:36π-Alkyl4.94
π-Lone pair2.81
VAL B:52π-Alkyl5.24
ASP B:129Carbon H-Bond3.01
PHE B:130H-Bond2.71
PRO B:132H-Bond2.18
π-Alkyl5.19
TYR B:161π-π Stacked5.62
π-Sigma3.66

2.CAA02−6.56ILE B:36π-Alkyl5.28
Pi-Lone pair2.89
VAL B:52π-Alkyl2.35
HIS B:51H-Bond2.08
SER B:135H-Bond1.90
TYR B:150π-Alkyl4.82

3.CAA03−6.60ILE B:36Alkyl3.94
π-Alkyl5.27
VAL B:52π-Alkyl5.34
PRO B:132H-Bond1.98

4.CAA04−6.45ILE B:36Alkyl3.83
π-Alkyl5.39
VAL B:52π-Alkyl5.31
PRO B:132H-Bond2.00

5.CAA05−6.85ARG B:543 H-Bonds1.75, 2.37, 2.63
PRO B:132H-Bond2.51
TYR B:150π-Alkyl5.22
TYR B:161π-Alkyl5.17

6.CAA06−6.01HIS B:51Carbon H-Bond3.26
π-π Stacked5.45
ASP B:75Pi-Anion3.28
SER A:83Carbon H-Bond3.07
MET A:84H-Bond1.95
ASN B:1522 H-Bonds1.78, 2.00
GLY B:153Pi-Donor H-Bond3.07

7.CAA07−6.66TRP B:50π-Alkyl5.07
VAL B:72Alkyl4.77
ILE A:86Alkyl4.06
GLY B:153H-Bond2.05
VAL B:154π-Sigma3.72
Alkyl4.16
VAL B:155H-Bond1.91
π-Alkyl5.07
Alkyl5.07

8.CAA08−6.81ILE B:36π-Alkyl5.29
Alkyl3.61
Pi-Lone pair2.95
HIS B:51H-Bond2.04
VAL B:52π-Alkyl5.25
SER B:135H-Bond1.86
TYR B:150π-Alkyl4.81
9.CAA09−6.75ILE B:36π-Alkyl5.45
Alkyl3.85
HIS B:51H-Bond1.98
VAL B:52π-Alkyl5.31
PRO B:132H-Bond1.85
TYR B:150π-Alkyl5.27
TYR B:161π-Sigma3.74
π-π Stacked4.53

10.CAA10−6.61ILE B:36Π-Alkyl5.24
Alkyl3.55
PRO B:132H-Bond1.83
π-Alkyl5.09
TYR B:161π-Alkyl3.61

11.CAA11−6.72HIS B:51H-Bond2.11
π-Cation4.83
π-π T-shaped5.20
ARG B:543 H-Bonds1.85, 2.56, 2.60
PRO B:132π-Alkyl5.22
SER B:135H-Bond2.20
TYR B:161π-π T-shaped3.90
π-Sigma5.11

12.CAA12−5.99ILE B:36π-Alkyl5.23
Alkyl3.47
VAL B:52π-Alkyl5.24
PRO B:132H-Bond1.98
GLY B:151H-Bond1.98

13.CAA13−6.66ILE B:36π-Alkyl5.26
Alkyl4.46
π-Lone pair2.95
HIS B:51H-Bond2.18
VAL B:52π-Alkyl5.24
ASP B:29H-Bond2.76
PHE B:130H-Bond1.97
PRO B:132H-Bond1.81
TYR B:161π-π Stacked4.67

14.CAA14−7.05HIS B:51π-Alkyl3.87
VAL B:52π-Alkyl5.33
Alkyl3.58
ASP B:29H-Bond2.39
PHE B:130H-Bond2.07
PRO B:132H-Bond1.97
Alkyl4.62
TYR B:161π-π Stacked4.35

15.CAA15−7.22ILE B:36Alkyl4.15
HIS B:51H-Bond2.13
VAL B:52π-Alkyl5.42
ASP B:29H-Bond1.91
PHE B:130H-Bond2.43
PRO B:132H-Bond1.73
TYR B:161π-π Stacked4.15
16.CAA16−7.03ILE B:36Alkyl4.14
HIS B:51H-Bond2.17
VAL B:52π-Alkyl5.37
ASP B:29H-Bond1.93
PHE B:130H-Bond2.56
PRO B:132H-Bond1.69
TYR B:161π-π Stacked4.16

17.CAA17−7.07VAL B:52π-Alkyl5.47
ARG B:542 H-Bonds2.02, 2.68
ASP B:29H-Bond2.73
PHE B:130H-Bond1.97
PRO B:132H-Bond2.20
TYR B:161π-π Stacked4.62

18.CAA18−6.23GLN B:35H-Bond2.34
ILE B:36π-Lone pair2.88
π-Alkyl5.20
VAL B:52π-Alkyl5.23
ASP B:29H-Bond2.99
PHE B:130H-Bond1.96
PRO B:132H-Bond1.81
TYR B:161π-π Stacked5.13

19.CAA19−7.74TRP B:50π-Alkyl5.04
VAL B:72Alkyl4.83
ILE A:86Alkyl4.03
GLY B:153H-Bond2.05
VAL B:154π-Sigma3.69
Alkyl4.09
VAL B:155H-Bond1.90
π-Alkyl5.07
Alkyl5.12

20.CAA20−7.18TRP B:50π-Alkyl5.08
VAL B:72Alkyl4.91
GLY B:153H-Bond2.09
VAL B:154π-Alkyl5.40
VAL B:155π-Alkyl4.83
Alkyl5.03
TYR B:161π-Alkyl5.00

21.CAA21−7.36TRP B:50π-Alkyl4.97
HIS B:51π-π Stacked4.44
VAL B:72Alkyl4.97
ASP B:75π-Cation3.85
PHE B:130Halogen3.10
GLY B:153H-Bond2.12
TYR B:161π-Alkyl3.98
π-π Stacked4.10

22.CAA22−7.14TRP B:50π-Alkyl5.10
HIS B:51π-π Stacked4.36
VAL B:72Alkyl5.07
ASP B:75π-Anion3.97
GLY B:153H-Bond2.12
TYR B:161π-Alkyl4.21
π-π Stacked4.18
23.CAA23−7.24ILE B:36π-Alkyl4.86
ARG B:54H-Bond2.28
PRO B:132π-Alkyl4.61
SER B:135Carbon H-Bond4.36
TYR B:161π-Alkyl4.48
2 π-Sigma3.71, 3.90

24.CAA24−6.56SER B:1353 H-Bonds1.99, 2.10, 3.01
VAL B:155π-Alkyl4.97

25.CAA25−6.70GLN B:35Halogen3.08
ILE B:36π-Alkyl4.95
Alkyl4.97
π-Lone pair2.80
VAL B:52π-Alkyl5.35
ASP B:29Carbon H-Bond2.97
PHE B:130H-Bond2.76
PRO B:132H-Bond2.12
π-Alkyl5.22
TYR B:161π-Sigma3.71
π-π Stacked5.58

26.CAA26−6.75GLN B:352 Halogen2.99, 3.68
ILE B:36π-Alkyl5.38
Alkyl5.26
π-Lone pair2.87
Carbon H-Bond4.14
Halogen3.37
VAL B:52π-Alkyl5.43
HIS B:51H-Bond2.19
PRO B:132Alkyl5.03
SER B:135H-Bond1.92
TYR B:150π-Alkyl4.75

27.CAA27−6.70ILE B:36π-Alkyl5.25
Alkyl3.95
VAL B:52π-Alkyl5.32
ASP B:292 Halogens2.78, 3.46
PHE B:130Halogen3.70
PRO B:132H-Bond1.97
TYR B:161π-Alkyl3.81

28.CAA28−6.52ILE B:36π-Alkyl5.26
Alkyl3.89
VAL B:52π-Alkyl5.35
ASP B:292 Halogens2.77, 3.65
PRO B:132H-Bond1.95
TYR B:161π-Alkyl3.70

29.CAA29−6.95ARG B:542 H-Bonds1.79, 2.19
ASP B:292 Halogens3.03, 3.60
PHE B:1302 Halogens3.15, 3.46
PRO B:132H-Bond2.84
π-Alkyl5.31
TYR B:161π-Alkyl3.75
π-Lone pair2.89
π-π Stacked5.48
30.CAA30−5.89HIS B:51H-Bond2.90
SER A:832 Halogens3.52, 3.60
MET A:84H-Bond2.07
2 Halogens2.07, 2.61
SER B:135H-Bond2.76
ASN B:152Halogen3.23
GLY B:153Halogen3.01
VAL B:155Alkyl5.36
Fig. 2

The 3D interaction of compound CAA15 (FEB: −7.22) against viral target NS2B/NS3pro.

Fig. 3

The 3D interaction of compound CAA16 (FEB: −7.03) against viral target NS2B/NS3pro.

Fig. 4

The 3D interaction of compound CAA17 (FEB: −7.07) against viral target NS2B/NS3pro.

Structure of cinnamic acid. DENV target used in docking. List of cinnamic acids and cinnamic amide derivatives. Cinnamic amide derivatives and their interactions. The 3D interaction of compound CAA15 (FEB: −7.22) against viral target NS2B/NS3pro. The 3D interaction of compound CAA16 (FEB: −7.03) against viral target NS2B/NS3pro. The 3D interaction of compound CAA17 (FEB: −7.07) against viral target NS2B/NS3pro.

Experimental Design, Materials and Methods

. Selection and retrieval of targets structures

The virtual screening was carried out on the homology model of the dengue virus's non-structural protein, NS2B/NS3pro developed by Wichapong et al [5]. The DENV-2 NS2B/NS3pro model was built based on the DENV-2 complex cofactor-protease using the crystal structure of NS2B/NS3pro West Nile Virus (WNV) as the template. The protein structure was prepared as a macromolecule prior to docking using AutoDock version 1.5.6 package (www.autodock.scrips.edu). Briefly, the protein preparation was done by removing the native ligand, tetrapeptide inhibitor (Bz-Nle-Lys-Ar-H) and water molecules, the addition of polar hydrogen and Kollmann charges.

Ligand preparation and molecular docking

The 3D structures of 30 cinnamic amide derivatives were constructed and energetically optimized using ChemDraw Professional 16.0. The minimised structures were saved in sdf format before being converted into pdb format using OpenBabel-3.1.1 software [6]. The validation of docking protocol was done by re-docking the inhibitor tetrapeptide (Bz-Nle-Lys-Ar-H) with the RMSD value not greater than 2.0 Å. The ligands were prepared by merging of non-polar hydrogen and assigned Gasteiger charged. The center of the grid box was employed around the protease active site at 23.038, 43.372, −0.316 in x, y, and z coordinate, respectively, with a box size of 60 × 60 × 60 dimensions and grid spacing 0.375 Å. The docking of ligands was run with the Lamarckian Genetics Algorithm (GA) search program applied to generate 100 runs. The binding modes of compounds were analyzed using Discovery Studio Client 2020 (www.accelrys.com). The identification of hit compound was identified based on the conformations with the ones of lowest free binding energy and of the most populated cluster.

CRediT authorship contribution statement

Nadia Mohamed Yusoff: Data curation, Investigation, Methodology, Software, Writing – original draft. Asnuzilawati Asari: Conceptualization, Supervision. Siti Nor Khadijah Addis: Methodology, Validation, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships which have or could be perceived to have influenced the work reported in this article.
SubjectChemistry
Specific subject areaMolecular docking
Type of dataTableImageFigure
How data were acquiredMolecular docking (AutoDock 4.2), ChemDraw Professional 16.0, OpenBabel GUI, Discovery Studio 2020 Client.
Data formatRawAnalyzed
Parameters for data collectionDocking score and interaction of the ligand with amino acid residues in the binding pocket
Description of data collectionThe structure of cinnamic amide derivatives was constructed and energy minimized using ChemDraw software.The minimized structures were docked on selected anti-viral targets using AutoDock software.
Data source locationInstitution: Universiti Malaysia TerengganuCity/Town/Region: Kuala Nerus, Kuala TerengganuCountry: Terengganu
Data accessibilityTables and Figures of the docking are accessible in the article.Molecular docking files for Figure 2–4 are available at https://data.mendeley.com/datasets/838gm89sr2/1. doi: 10.17632/838gm89sr2.1
  4 in total

Review 1.  The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development.

Authors:  Dahai Luo; Subhash G Vasudevan; Julien Lescar
Journal:  Antiviral Res       Date:  2015-04-02       Impact factor: 5.970

2.  Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.

Authors:  Kanin Wichapong; Somsak Pianwanit; Wolfgang Sippl; Sirirat Kokpol
Journal:  J Mol Recognit       Date:  2010 May-Jun       Impact factor: 2.137

3.  Open Babel: An open chemical toolbox.

Authors:  Noel M O'Boyle; Michael Banck; Craig A James; Chris Morley; Tim Vandermeersch; Geoffrey R Hutchison
Journal:  J Cheminform       Date:  2011-10-07       Impact factor: 5.514

Review 4.  Cinnamic Acid Derivatives and Their Biological Efficacy.

Authors:  Ngonidzashe Ruwizhi; Blessing Atim Aderibigbe
Journal:  Int J Mol Sci       Date:  2020-08-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.